biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) announces that it has been granted Patent # 2,230,372 by the Canadian Intellectual Property Office. “This is a significant and important patent for securing a large unmet need for a biomarker that can act as an aid to diagnosing and monitoring Alzheimer's disease and for identifying new therapeutics for Alzheimer's disease. The issuance of this patent follows double blind validation studies completed by unrelated groups of scientists, (Feldman et al;
and Kim et al;
) thereby validating this emerging biomarker under the strictest experimental design and conditions.
The effectiveness of biomarker as an aid to diagnosing and monitoring Alzheimer's disease in bodily fluids is based on a noninvasive simply single immunoassay (blood test), to monitor the possible or probable appearance of the disease by measuring the biomarker on a yearly basis. Equally as significant, it may enable physicians to monitor the effectiveness of treatments and emerging therapeutics they are prescribing for their patients to combat the progression of this disease.
This technology may therefore allow the screening and enablement of new therapeutic approaches where the efficacy can be rapidly assessed by monitoring the levels of the biomarker. This biomarker provides a major breakthrough for diagnosing and identifying curative approaches for this dreadful disease”. – Rob Hutchison CEO, biOasis Technologies Inc.
About biOasis
biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It obtained extensive and comprehensive intellectual property (the “IP”) from the University of British Columbia. The Company is focused on
|
|
the validation and commercialization of emerging biomarkers as aids to diagnose and monitor Alzheimer's disease.
The Alzheimer's Association reports that a n estimated 24-million+ people currently live with dementia worldwide, and this figure is projected to increase to 81 million by 2040 . According to the report, "An Estimate of the Total Worldwide Societal Costs of Dementia in 2005" by the Alzheimer's Association, the total worldwide cost of dementia care was estimated to be US$315.4 billion annually. North America and Europe account for 77% of the worldwide economic and social burden of this disease. The burden is highest in the U.S.A. (US$76 billion), followed by Japan (US$34 billion) and China (US$28 billion).
The demographics suggest that the costs associated with Alzheimer's will rise significantly as the global population ages. Earlier diagnosis will enable earlier (and more effective) treatment and allow the identification and implementation of new therapeutics that will improve the lives of Alzheimer's and their caregivers.
To find out more about biOasis Technologies Inc. visit www.bioasis.ca and or contact Rob Hutchison CEO at 604-644-1232.
“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”
On Behalf of the Board of Directors
“ Robin Hutchison ”
Robin Hutchison, Chairman and CEO
|
